Metastatic Pancreatic Cancer - Pipeline Insight, 2025
Description
DelveInsight’s, Metastatic Pancreatic Cancer - Pipeline Insight, 2025,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Metastatic Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Metastatic Pancreatic Cancer: Overview
Pancreatic cancer refers to the carcinoma arising from the pancreatic duct cells, pancreatic ductal carcinoma. It is the fourth leading cause of cancer deaths in the United States. The 5-year survival rate in the United States ranges from 5% to 15%. The overall survival rate is only 6%. Surgical resection is the only current option for a cure, but only 20% of pancreatic cancer is surgically resectable at the time of diagnosis.
In metastatic pancreatic cancer, surgery is used only for symptom control, such as for pain, jaundice, or gastric outlet obstruction. Radiation may be used for symptom relief, as well. Metastatic Pancreatic cancer has clearly spread to other organs, so surgery cannot remove the cancer.
""Metastatic Pancreatic Cancer - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic Pancreatic Cancer pipeline landscape is provided which includes the disease overview and Metastatic Pancreatic Cancer treatment guidelines. The assessment part of the report embraces, in depth Metastatic Pancreatic Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
Motixafortide: BioLineRx
Motixafortide (formerly known as BL-8040/BKT140) is a novel selective inhibitor of the CXCR4 chemokine receptor. CXCR4, is a well validated therapeutic target that is involved in the mobilization and trafficking of hematopoietic stem cells, immune cells and cancer cells from the bone marrow and the lymph nodes to the peripheral blood. Motixafortide is being developed as a platform for several indications including mobilization of hematopoietic stem cells (HSCs) for autologous transplantations, treatment of solid tumors, and other hematological malignancies.
Fuzuloparib: Jiangsu Hengrui Pharmaceuticals
Fuzuloparib is a small molecule, orally active PARP inhibitor being developed by Jiangsu Hengrui Pharmaceuticals Co for the treatment of solid cancers. Fuzuloparib has been approved in China for the treatment of ovarian cancer (including fallopian tube cancer or primary peritoneal cancer), and phase II and III trials are investigating fuzuloparib for the treatment of other solid cancers, including cancers of the pancreas, breast, prostate and lungs.
HP518: Hinova Pharmaceuticals
HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.
Further product details are provided in the report……..
Metastatic Pancreatic Cancer: Therapeutic Assessment
This segment of the report provides insights about the Metastatic Pancreatic Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Metastatic Pancreatic Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic Pancreatic Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic Pancreatic Cancer drugs.
Metastatic Pancreatic Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Metastatic Pancreatic Cancer: Overview
Pancreatic cancer refers to the carcinoma arising from the pancreatic duct cells, pancreatic ductal carcinoma. It is the fourth leading cause of cancer deaths in the United States. The 5-year survival rate in the United States ranges from 5% to 15%. The overall survival rate is only 6%. Surgical resection is the only current option for a cure, but only 20% of pancreatic cancer is surgically resectable at the time of diagnosis.
In metastatic pancreatic cancer, surgery is used only for symptom control, such as for pain, jaundice, or gastric outlet obstruction. Radiation may be used for symptom relief, as well. Metastatic Pancreatic cancer has clearly spread to other organs, so surgery cannot remove the cancer.
""Metastatic Pancreatic Cancer - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic Pancreatic Cancer pipeline landscape is provided which includes the disease overview and Metastatic Pancreatic Cancer treatment guidelines. The assessment part of the report embraces, in depth Metastatic Pancreatic Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Metastatic Pancreatic Cancer. The therapies under development are focused on novel approaches to treat/improve Metastatic Pancreatic Cancer.
Motixafortide: BioLineRx
Motixafortide (formerly known as BL-8040/BKT140) is a novel selective inhibitor of the CXCR4 chemokine receptor. CXCR4, is a well validated therapeutic target that is involved in the mobilization and trafficking of hematopoietic stem cells, immune cells and cancer cells from the bone marrow and the lymph nodes to the peripheral blood. Motixafortide is being developed as a platform for several indications including mobilization of hematopoietic stem cells (HSCs) for autologous transplantations, treatment of solid tumors, and other hematological malignancies.
Fuzuloparib: Jiangsu Hengrui Pharmaceuticals
Fuzuloparib is a small molecule, orally active PARP inhibitor being developed by Jiangsu Hengrui Pharmaceuticals Co for the treatment of solid cancers. Fuzuloparib has been approved in China for the treatment of ovarian cancer (including fallopian tube cancer or primary peritoneal cancer), and phase II and III trials are investigating fuzuloparib for the treatment of other solid cancers, including cancers of the pancreas, breast, prostate and lungs.
HP518: Hinova Pharmaceuticals
HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.
Further product details are provided in the report……..
Metastatic Pancreatic Cancer: Therapeutic Assessment
This segment of the report provides insights about the Metastatic Pancreatic Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Metastatic Pancreatic Cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Metastatic Pancreatic Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic Pancreatic Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic Pancreatic Cancer drugs.
Metastatic Pancreatic Cancer Report Insights
- Metastatic Pancreatic Cancer Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Metastatic Pancreatic Cancer drugs?
- How many Metastatic Pancreatic Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic Pancreatic Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Metastatic Pancreatic Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Metastatic Pancreatic Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Jiangsu HengRui Medicine
- Eleison Pharmaceuticals
- Panbela Therapeutics
- SynerGene Therapeutics
- Salspera
- BioLineRx
- Ocuphire Pharma
- Incyte Corporation
- Eli Lilly and Company
- Rexahn Pharmaceuticals
- AB Science
- Takeda Oncology
- Fuzuloparib
- Glufosfamide - Eleison Pharmaceuticals
- SBP 101
- SGT-53
- MDB 401 B
- Motixafortide
- Epacadostat
- Retifanlimab
- Roducitabine
- Olaratumab
- RX 0201
- Masitinib
- Simurosertib
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Metastatic Pancreatic Cancer: Overview
- What is Metastatic Pancreatic Cancer?
- Types of Metastatic Pancreatic Cancer
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Metastatic Pancreatic Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Rucaparib: Eleison Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- MDB 401 B: Panbela Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- SBP 101: Takeda Oncology
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Metastatic Pancreatic Cancer Key Companies
- Metastatic Pancreatic Cancer Key Products
- Metastatic Pancreatic Cancer- Unmet Needs
- Metastatic Pancreatic Cancer- Market Drivers and Barriers
- Metastatic Pancreatic Cancer- Future Perspectives and Conclusion
- Metastatic Pancreatic Cancer Analyst Views
- Metastatic Pancreatic Cancer Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
